Company intelligence / Profile preview

KeyBioscience

Lugano, Ticino, Switzerland

Ownership: Private
Development stage: Other

Overview

KeyBioscience focuses on the development of Dual-Acting Amylin and Calcitonin Receptor Agonists (DACRAs) for metabolic and musculoskeletal diseases. In October 2024, the company extended its strategic collaboration with Eli Lilly, granting Lilly worldwide rights to develop and commercialize DACRA molecules. The lead program, KBP-336, is advancing into Phase 2 clinical trials for the treatment of obesity and osteoarthritis pain.

Therapeutic areas: EndocrinologyRheumatologyGastroenterology
Modalities: Peptides
Industry: Biotech

Partnerships

Eli Lilly

Beyond the preview

Go deeper on KeyBioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KeyBioscience.

Explore the full profile